Bioheart, Inc. in Partnership With NorthStar on Physician Training in Stem Cell Techniques
Published: Dec 10, 2012
SUNRISE, FL--(Marketwire - December 10, 2012) - Bioheart Inc. (OTCQB: BHRT) previously announced that it is working with NorthStar Biotech to help promote regenerative medicine. NorthStar has announced that it will subsidize physicians to participate in the Ageless Regenerative Institute stem cell training program. The fully accredited CME training program includes a didactic lecture series followed by hands-on clinical training for physicians to learn to isolate stem cells for immediate use in their patients. The Ageless Regenerative Institute has successfully trained over 200 physicians and these physicians are utilizing both adipose and bone marrow derived stem cells as well as platelet rich plasma for orthopedics, aesthetics and other degenerative diseases.
With the new NorthStar/Bioheart program, this select group of physicians have the opportunity to receive full funding for the training and join a network of physicians who will offer in-clinic stem cell therapies. Once these physicians commence IRB-approved in-clinic services, Bioheart will receive royalties for the use of these fee-for-service procedures. Initial projections have not been announced by NorthStar.
"Physicians have for years evaluated and considered stem cell treatments as a potential alternative for a subset of our patient population. This program helps educate doctors and allows us a viable opportunity to expand our treatment portfolio for patients in need," said board-certified Miami internist Dr. Antonio Blanco.
Bioheart's president and CEO Mike Tomas said, "The training programs at the Ageless Regenerative Institute provide physicians with extraordinary regenerative medicine capabilities. We are fortunate to partner with Northstar to bring these therapies to the clinic."
Physicians interested in applying to participate in the program should contact firstname.lastname@example.org.
About Bioheart, Inc.
Bioheart is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheart's goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.
Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit www.bioheartinc.com, or visit us on Facebook: Bioheart and Twitter @BioheartInc.
About Ageless Regenerative Institute, LLC
The Ageless Regenerative Institute (ARI) is an organization dedicated to the standardization of cell regenerative medicine. The Institute promotes the development of evidence-based standards of excellence in the therapeutic use of adipose-derived stem cells through education, advocacy, and research. ARI has a highly experienced management team with experience in setting up full scale cGMP stem cell manufacturing facilities, stem cell product development & enhancement, developing point-of-care cell production systems, developing culture expanded stem cell production systems, FDA compliance, directing clinical & preclinical studies with multiple cell types for multiple indications, and more. ARI has successfully treated hundreds of patients utilizing these cellular therapies demonstrating both safety and efficacy. For more information about regenerative medicine please visit www.agelessregen.com.
Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
13794 NW 4th Street
Sunrise, FL 33325